Navigation Links
Cochrane review on use of rectal artesunate for severe malaria
Date:5/30/2014

Researchers from the Cochrane Infectious Diseases Group, hosted at LSTM, conducted an independent review of the effects of pre-referral rectal artesunate for people with severe malaria, published in the Cochrane Library today. The review follows a large trial of rectal artesunate in 2009 which led the World Health Organization to recommend its use.

Severe malaria is a serious medical condition caused by infection with the Plasmodium parasite. It is treated by giving injections of antimalarial drugs, which need to be started as quickly as possible to reduce the risk of death and brain damage. In some rural areas where malaria is common, injections are unavailable and people often die before reaching hospital. In these areas rectal artesunate could feasibly be administered by volunteers without formal healthcare training, to start treatment before transporting the patient.

The Cochrane review authors searched extensively for other trials, but only the single trial from 2009 directly assessed pre-referral treatment. This trial enrolled over 17,000 patients at various sites across Ghana, Tanzania and Bangladesh, and trained village volunteers to recognize the symptoms of severe malaria, administer rectal artesunate, and refer all patients to hospital.

At the African sites, only children aged 6 to 72 months were enrolled and there were fewer deaths with rectal artesunate than with placebo. This expected finding was replicated in Asia, but complicated by the unexpected finding of more deaths with artesunate in older children (aged >72 months) and adults. The trial was well designed to minimize bias, but the number of deaths in the older age group was very low. Consequently, there is the possibility that this finding occurred by chance but without further trials neither the trial authors, nor the review authors were able to reliably explain this finding.

Joseph Okebe, the lead author of the review said: "In rural areas without access to injectable antimalarials rectal artesunate probably reduces deaths in young children. However, the low quality evidence that it is harmful in older children and adults must be taken into account when formulating national policies on pre-referral treatment."


'/>"/>

Contact: Clare Bebb
c.bebb@liv.ac.uk
44-015-170-53135
Liverpool School of Tropical Medicine
Source:Eurekalert

Related medicine news :

1. Wound care meta-review draws firm conclusions from Cochrane published studies
2. Cochrane finds no reliable evidence on effectiveness of electric fans in heatwaves
3. Omega-3 Supplements No Help Against Repeat Heart Trouble: Review
4. AADR comments on review that validates association between oral health and heart health
5. IUDs Work as Emergency Contraceptive: Review
6. ICU stays for worst asthma drop 74 percent, review finds
7. Antiretroviral treatment for preventing HIV infection: an evidence review for physicians
8. TheBestHeartRateMonitorReviews.com Announces The Top 3 Heart Rate Monitors
9. US Drug Watchdog Now Offers To Get A Free Legal Review For All DePuy ASR Recipients Who Received A Letter From Broadspire About Their Recalled DePuy Hip Implant
10. University of Nevada School of Medicine researcher reviews muscular dystrophy therapies
11. Metabolic Cooking Review For Karine Losier and Dave Ruel's Diet And Cookbook Program Released
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Einstein Medical is proud to ... the latest news and commentary at the 2016 ASCRS/ASOA Symposium and Congress, which takes ... Society of Cataract and Refractive Surgery and the American Society of Ophthalmic Administrations will ...
(Date:5/5/2016)... ... May 05, 2016 , ... Phycologia – ... (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao tested the magnitude of ... observed that when photosynthetically active radiation (i.e. the white light in our visible ...
(Date:5/5/2016)... ... May 05, 2016 , ... Every year 220 ... heartfelt wishes of these children. The wishes provide hope and motivation through ... CEO of Make-A-Wish Mississippi, Brent Wilson said, “In 2016, the organization will grant ...
(Date:5/5/2016)... ... 05, 2016 , ... Long Island’s fastest growing comprehensive eye care provider, ... surgeon, Kathleen Van Valkenburg, MD as part of their ongoing effort to increase ophthalmic ... and managing partner of North Shore Eye Care. , “We are extremely proud ...
(Date:5/5/2016)... ... ... TIME for Kids and The ZAC Foundation – a national leader in drowning ... million children with important water safety messages before summer break begins. , ... in children one to 6 years of age. TIME for Kids and The ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 Valeritas ... of an alternative public offering (APO). This was accomplished ... company, Valeritas, Inc. and a private placement of approximately ... $5.00 per share. Under the terms of ... 2016, Valeritas Holdings, Inc. will trade on the OTC ...
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Acute Ischemic ... 2016"  report to their offering.  ... Global Acute Ischemic Stroke Market ... insights into Acute Ischemic Stroke pipeline products, ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Actinic Keratosis Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Actinic Keratosis epidemiology, Actinic Keratosis market valuations ...
Breaking Medicine Technology: